Investment Rating - The investment rating for the healthcare industry is "Positive" and maintained [14] Core Insights - The funding levels for Chinese innovative pharmaceutical companies are increasing, leading to a gradual improvement in the research and development (R&D) investment sentiment within the industry. This is expected to usher in a new cycle of prosperity for the innovative drug industry chain [5][12] - The trend of external business development (BD) is likely to benefit the domestic early-stage research industry significantly, as new business models allow early-stage projects to become tradable and monetizable assets, enhancing R&D investment returns [13] Summary by Sections Innovative Chain Development Review - Before 2020, multiple factors converged to initiate a significant rise in China's innovative drug sector, leading to the rapid development of the innovative chain, including CXO and life sciences services [10][30] - From 2020 to the first half of 2022, the global public health crisis accelerated capital inflow into the biopharmaceutical sector, resulting in high demand and a leap in the innovative chain segment, which also triggered a wave of IPOs and substantial supply-side expansion [10][39] - The second half of 2022 to 2024 saw a transition from a heated to a cooling phase, with a significant shift in supply-demand dynamics leading to industry internal competition and pressure on revenues and profit margins [10][54][57] Improvement in R&D Investment Sentiment - Starting from 2025, the R&D investment sentiment in China's innovative drug sector is expected to improve, with companies experiencing increased funding levels. The total amount raised through IPOs and additional offerings in 2025 is projected to reach 201.5 billion yuan, a 145% year-on-year increase [11][62] - The potential milestone payments from external BD are expected to reach 880.5 billion yuan in 2025, marking a 185.9% year-on-year increase, indicating a robust funding environment for innovative drug companies [11] Benefits to Early-stage Research Industry - The new external BD business model enhances the R&D investment return rates for Chinese innovative drug companies, thereby increasing their willingness to invest in R&D [11][13] - The early-stage research industry, including drug discovery CROs and clinical trial services, is expected to benefit significantly from the external BD trend, with leading companies in these segments poised for rapid growth [13]

Core Viewpoint - Jiuzhou Pharmaceutical (603456) emphasizes that its stock performance is influenced by multiple factors including market conditions and sector rotation, while the company remains focused on its core business development and enhancing its competitive edge [1] Group 1 - The company will continue to enhance its core competitiveness through standardized operations and transparent communication with the market [1] - Jiuzhou Pharmaceutical aims to convey long-term investment value to the market [1]

Core Viewpoint - The company, Zhejiang Jiuzhou Pharmaceutical Co., Ltd., has announced the use of idle raised funds for cash management, specifically to redeem maturing cash management products and continue cash management activities [1][2]. Cash Management Overview - The entrusted party for cash management is Agricultural Bank of China, Changshu Economic Development Zone Branch [2]. - The board of directors approved the use of up to RMB 1 billion of idle raised funds for cash management, ensuring that it does not affect the construction and use of investment projects [2][7]. - The cash management products include high-security and liquid investment options such as structured deposits, time deposits, large certificates of deposit, notice deposits, income certificates, and bank or brokerage wealth management products [2][7]. Cash Management Details - The amount used for cash management is RMB 30 million [4][5]. - The cash management product involved is a large certificate of deposit with a duration of 6 months [5]. - The company has previously raised RMB 2.5 billion through a non-public offering of shares, with a net amount of RMB 2.49 billion after deducting issuance costs [6]. Purpose of Cash Management - The purpose of cash management is to enhance the efficiency of fund utilization while ensuring the safety of funds and the normal operation of investment projects [3][10]. Risk Management - The company emphasizes that the cash management will only involve high-security and liquid products, minimizing investment risks [8][9]. - Strict adherence to prudent investment principles and confidentiality regarding cash management activities is mandated [9]. Impact on Company - The cash management activities are not expected to affect the implementation of investment projects or the company's future operations, financial status, or cash flow significantly [10].

Group 1 - The core viewpoint of the article emphasizes that Jiuzhou Pharmaceutical values investor returns and is open to disclosing any share repurchase plans in a timely manner [2]

Group 1 - The company, Jiuzhou Pharmaceutical, stated that it will comply with regulatory requirements for information disclosure in response to investor inquiries on the interactive platform [2]

证券代码：603456 证券简称：九洲药业 公告编号：2026-004 浙江九洲药业股份有限公司 关于使用闲置募集资金进行现金管理到期赎回并 继续进行现金管理的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 现金管理受托方：中国农业银行股份有限公司常熟经济开发区支行（以 下简称"农业银行常熟经济开发区支行"）； 履行的审议程序：浙江九洲药业股份有限公司（以下简称"公司"、"九洲 药业"）于 2025 年 12 月 9 日召开的第八届董事会第十九次会议、第八届审计委 员会第十三次会议，审议通过了《关于使用闲置募集资金进行现金管理的议案》， 同意公司及子公司在保障资金安全及确保不影响募集资金投资项目建设和使用 计划的前提下，使用不超过人民币 10 亿元的闲置募集资金适时购买安全性高、 流动性好的投资产品（包括但不限于结构性存款、定期存款、大额存单、通知存 款、收益凭证及银行或券商理财产品等），不得为非保本型。期限为自董事会审 议通过之日起不超过 12 个月，单笔投资产品的期限不超过 12 个月。本事项无需 提 ...

企业认缴出资总额的 12.987%。根据《上海证券交易所股票上市规则》及《公司 章程》的有关规定，本次对外投资事项无需提交公司董事会、股东会审议批准， 亦不构成关联交易和重大资产重组。 具体内容详见公司于 2025 年 12 月 23 日披露于上海证券交易所官网 （www.sse.com.cn）的《浙江九洲药业股份有限公司关于全资子公司参与投资嘉 兴隆峰创业投资合伙企业（有限合伙）的公告》（公告编号：2025-075）。 证券代码：603456 证券简称：九洲药业 公告编号：2026-003 浙江九洲药业股份有限公司关于全资子公司参与 投资嘉兴隆峰创业投资合伙企业（有限合伙）的进展 公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 投资标的名称 | | | 嘉兴隆峰创业投资合伙企业（有限合伙） | | | --- | --- | --- | --- | --- | | 投资金额（万元） | 1,000 | | | | | 投资进展阶段 | 完成 | 终止 | 交易要素变更 | √进展 | | 特别 ...

Core Viewpoint - Jiuzhou Pharmaceutical (603456) emphasizes that its stock performance is influenced by multiple factors including market conditions and sector rotation, while the company remains focused on its core business development to enhance sustainable profitability and governance structure [1] Group 1 - The company aims to actively communicate its core value to the capital market [1] - Jiuzhou Pharmaceutical is committed to creating long-term and stable investment returns for its investors [1]

Core Viewpoint - The report highlights the significant growth and development of China's Contract Research Organization (CRO) industry, driven by a comprehensive policy framework and regulatory reforms that enhance innovation and operational efficiency in the pharmaceutical sector [1][3][9]. Group 1: Industry Overview - The main listed companies in China's CRO industry include WuXi AppTec (603259.SH), Kanglong Chemical (300759.SZ), Tigermed (300347.SZ), Kelaiying (002821.SZ), Zhaoyan New Drug (603127.SH), Jiuzhou Pharmaceutical (603456.SH), Haoyuan Pharmaceutical (688131.SH), Boteng Co., Ltd. (300363.SZ), Chengdu XianDao (688222.SH), and Yaoshi Technology (300725.SZ) [1]. - The CRO industry is recognized as a strategic emerging industry that supports pharmaceutical innovation, transitioning China from a major pharmaceutical market to a strong one [1]. Group 2: Policy Framework - The policy framework for the CRO industry is centered around the National Medical Products Administration (NMPA) and includes collaboration with other regulatory bodies such as the National Health Commission (NHC) and the Drug Administration (CDR) [3]. - Key regulatory measures include the Marketing Authorization Holder (MAH) system, implicit licensing for clinical trials, Good Laboratory Practice (GLP) and Good Clinical Practice (GCP) certifications, and priority review and approval processes [3]. Group 3: Industry Support Policies - National policies provide financial support through initiatives like the "Major New Drug Creation" program, tax reductions for high-tech enterprises, and increased deductions for R&D expenses, which lower operational costs for the industry [6]. - Local governments implement differentiated policies that align with regional industrial characteristics, including subsidies for innovative drug development and funding for CRO platform construction [6]. Group 4: Drug Review Reforms - Recent reforms in drug review processes have significantly improved approval efficiency, reducing the average clinical trial review time from 420 days to 30 days in pilot areas, and addressing a backlog of 22,000 cases [9][12]. - The definition of new drugs has shifted from "China New" to "Global New," aligning with international standards and enhancing the quality of innovation [12]. Group 5: Future Trends - The future of the CRO industry in China is expected to be driven by a robust policy framework, with trends including deeper collaboration in service models, increased application of AI and digital platforms, and a focus on specialized market segments [13]. - The competitive landscape is anticipated to evolve with the rise of domestic leaders and accelerated internationalization, benefiting from improved mechanisms for mutual recognition of clinical trial data [13].

Core Insights - The CRO industry in China is experiencing significant growth, with the market size expected to expand from 90 billion yuan in 2021 to 126 billion yuan by 2024, reflecting a compound annual growth rate (CAGR) of 28%, which is substantially higher than the global average of 10% [13][26] - The industry is characterized by a clear competitive landscape, with WuXi AppTec as the dominant player, achieving revenue exceeding 20 billion yuan, while other key players include Kanglong Chemical, Tigermed, and Kelun Pharmaceutical [17][20] Industry Overview - Contract Research Organizations (CROs) are specialized entities that undertake drug development responsibilities on behalf of pharmaceutical companies, helping to reduce costs and risks while ensuring compliance [1] - The CRO industry is divided into preclinical and clinical segments, with preclinical CROs focusing on drug discovery and safety evaluations, while clinical CROs handle clinical trials and data management [1] Industry Development History - The CRO industry in China began in 1996 with the establishment of the first joint venture, and has evolved from a lack of formal organizations to a competitive landscape dominated by local leaders [9] - The industry has undergone significant changes, including the implementation of Good Clinical Practice (GCP) in 2003 and the introduction of the Marketing Authorization Holder (MAH) system, which has facilitated the growth of CRO services [11] Market Demand and Growth - The number of New Drug Applications (NDA) in China has been increasing, from 210 in 2021 to an expected 320 by 2024, driving demand for CRO services [14] - The global CRO market is projected to grow from 71 billion USD in 2021 to 90 billion USD by 2024, driven by increased healthcare demands due to aging populations and the COVID-19 pandemic [13] Competitive Landscape - The competitive structure of the Chinese CRO industry is categorized into three tiers, with WuXi AppTec leading the first tier, followed by Kanglong Chemical and Tigermed in the second tier, and smaller firms in the third tier [17] - Most companies are diversifying their services to include both CRO and CDMO (Contract Development and Manufacturing Organization) capabilities, enhancing operational efficiency [20] Regional Market Dynamics - The Yangtze River Delta region dominates the CRO market in China, accounting for approximately 43% of the market share, followed by the Beijing-Tianjin-Hebei region at 23% and the Pearl River Delta at 19% [23] Future Outlook - The Chinese CRO market is expected to continue its growth trajectory, potentially exceeding 144 billion yuan by 2028, supported by favorable policies and increasing demand for innovative therapies [26] - Despite challenges such as rising compliance costs and market saturation, the overall outlook remains positive, with expectations of sustained double-digit growth over the next five years [26]